You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-948-ESGO Neoadjuvant Chemotherapy (NACT) and Interval Debulking Surgery (IDS) in a Group of Patients with Advanced Stage Epithelial Ovarian Cancer, Unsuitable for Upfront Surgery

Alerts

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-948-ESGO Neoadjuvant Chemotherapy (NACT) and Interval Debulking Surgery (IDS) in a Group of Patients with Advanced Stage Epithelial Ovarian Cancer, Unsuitable for Upfront Surgery
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address